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ABSTRACT
Background: Chronic gastritis is commonly found with complains of dyspepsia, which may decrease work 
productivity. Imbalance between agressive and defensive factors is the cause of chronic gastritis. Therapy is 
mostly directed to the agressive factors, particularly gastric acid and very few studies are directed on defensive 
factors. Mucus is the first defense mechanism of gastric mucosa. Fucoidan is a phytopharmaca, which is thought 
to increase the thickness of gastric mucosa. The objective of this study was to know the thickness of gastric 
mucosa in patients with chronic gastritis and to evaluate the effect of fucoidan to the gastric mucosa thickness 
in patients with chronic gastritis.
Method: In this double-blinded randomized clinical trial study, 41 patients in the Endoscopy Unit Cipto 
Mangunkusumo Hospital between October 2009 and October 2010 were enrolled consecutively. Selected patients 
were divided into 2 groups: a group was given fucoidan and another group was given placebo. Statistical analysis 
was done using T-test.
Results: Of 41 chronic gastritis patients, only 34 patients completed this study. There was difference of mucus 
thickness of gastric mucosa in patients with chronic gastritis; in the antrum 42.59 µm (± 8.67) and in the corpus 
44.28 µm (± 9.64). This study also showed that fucoidan administration increased the mucus thickness in the 
antrum by 7.42 µm and in the corpus by 7.74 µm compared to placebo significantly. 
Conclusion: Fucoidan increased the mucus thickness of gastric mucosa in patients with chronic gastritis.
Keywords: mucus thickness, chronic gastritis, fucoidan
ABSTRAK
Latar belakang: Gastritis kronik seringkali ditemukan dengan keluhan dispepsia yang dapat menurunkan 
produktivitas kerja. Ketidakseimbangan antara faktor agresif dan defensif merupakan penyebab gastritis kronik. 
Terapi sebagian besar ditujukan terhadap faktor agresif terutama pada asam lambung. Namun saat ini sedikit 
sekali penelitian tentang faktor defensif. Mukus merupakan lini pertahanan pertama mukosa lambung yang 
merupakan faktor defensif, sedangkan fucoidan yang merupakan fitofarmaka diperkirakan dapat menambah 
ketebalan mukosa lambung. Tujuan penelitian ini yaitu untuk mengetahui ketebalan mukosa lambung pada 
pasien gastritis kronik dan efek fucoidan terhadap ketebalan mukosa lambung pada pasien gastritis kronik.
Metode: Penelitian ini menggunakan desain uji klinik acak tersamar ganda pada 41 pasien di Unit Endoskopi 
Rumah Sakit Cipto Mangunkusumo pada bulan Oktober 2009 hingga Oktober 2010 secara konsekutif. Pasien 
yang terpilih dibagi menjadi 2 kelompok yaitu kelompok dengan fucoidan dan plasebo. Analisis statitistik 
dilakukan dengan menggunakan uji-T. 
Hasil: Dari 41 pasien gastritis kronik hanya 34 pasien yang mengikuti penelitian hingga selesai. Didapatkan 
perbedaan ketebalan mukus mukosa lambung pada pasien gastritis kronik di antrum 42.59 µm (± 8.67) dan 
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di korpus 44.28 µm (± 9.68). Hasil penelitian juga menunjukkan pemberian fucoidan menambah ketebalan 
mukus antrum 7.42 µm dan mukus korpus 7.74 µm dibandingkan plasebo secara bermakna.
Kesimpulan: Fucoidan menambah ketebalan mukus mukosa lambung pada pasien gastritis kronik. 
Kata kunci: ketebalan mukus, gastritis kronik, fucoidan
INTRODUCTION
Gastritis is a health problem most commonly 
found in the clinic, which causes huge health cost 
and decreases work productivity.1 Imbalance between 
agressive and defensive factors in the stomach is 
the mechanism how gastritis developed. A lot of 
medicines have been found to be beneficial in 
overcoming the agressive factors, such as proton pump 
inhibitors (PPI) and histamine 2 receptor antagonist 
(H2A). Different with agressive factors, till date there 
is only few therapy to improve defensive factors. 
However, there are several agressive factors which 
influence the mucus thickness, and many medicines 
are objected to overcome these agressive factors.2
Mucus is a sulphate containing polysaccharide 
which has anti-peptic activity through ionic binding 
with proteins on the mucosal surface, which are pepsin 
substrates, and not through enzymatic inhibition.2 
Mucus of the gastric mucosa plays role in the first 
defense mechanism of the stomach. Therefore, its 
role is very important before irritant substances reach 
the epithelial cells of the gastric mucosa. Gastric 
mucosa is protected from acid and pepsin by mucus, 
which is a proteoglycan secreted by epithelial cells 
of gastric mucosal surface. There is no data about the 
mucus thickness of gastric mucosa in patients with 
chronic gastritis, which is possibly thinner compared 
to healthy individuals. 
It is reported that fucoidan administered orally is 
proven to be effective in treating and preventing gastric 
ulcer in animal studies.3 Fucoidan polysaccharide is also 
known to be effective in cell proliferation, particularly 
in digestive tract and also has some benefits, such as: 
may resolve inflammation in the stomach (gastritis) as 
well as ulcer.4 In the study conducted by Yamamoto 
which examined the effect of tea containing fucoidan 
derived from mozuku in patients with gastric ulcer 
and non-ulcer dyspepsia, improvement in subjective 
symptoms was found.5 Many studies have reported that 
fucoidan administration improved ulcers. However, 
none evaluated the effect of fucoidan in patients with 
chronic gastritis, particularly the effect towards mucus 
thickness. Fucoidan has cytoprotective effect to the 
gastric mucosa, protecting epithelial cells of the gastric 
mucosa from irritant substances. This will enable 
the vascularization of these epithelial cells to have 
function properly and optimally, predominantly in the 
mucus production and will lead to increase production 
of growth factors important for re-epithelialization. 
Therefore, this clinical study was performed to evaluate 
the effect of fucoidan to mucus thickness of gastric 
mucosa in patients with chronic gastritis.
METHOD
This study is a double-blinded randomized clinical 
trial to evaluate the effect of fucoidan to mucus 
thickness of the gastric mucosa in chronic gastritis 
patients between October 2009 and April 2010 in 
Endoscopy Unit, Cipto Mangunkusumo Hospital. 
Sample selection was done consecutively. Patients 
aged 18-60 years old, suffering from chronic gastritis 
which has been confirmed through endoscopy, and 
has given informed consent to participate in this study 
were included.
Exclusion cri teria included (1) patients 
contraindicated to undergo esophagoduodenoscopy 
(EGD), endoscopy, biopsy, or to consume fucoidan, 
such as: individuals with hematologic disturbance 
(e.g. pregnant or lactating women), hypersentive 
to fucoidan (2) condition which influence mucus 
thickness and changes of mucus thickness, for 
example: on medication which may induce gastritis 
or ulcer, such as: non-steroid anti-inflammatory 
drugs (NSAIDs), alcoholism, pylori stenosis, history 
of gastric surgery, renal abnormalities (creatinine > 
2 mg/dL), liver disease [abnormal aspartate 
transaminase (AST)/alanine transaminase (ALT)] 
> 2 times upper limit of normal values, bilirubin > 
2 mg/dL), congestive gastropathy due to cirrhosis, 
congestive heart failure, consuming gastroprotective 
medicines, such as teprenon, sucralfate, acid suppressor 
agents (PPI, H2A), antibiotics, mesalazine (salofalk), 
and (3) conditions which need to be treated with PPI/
H2A, such as erosive or ulcerative esophagitis, peptic 
ulcer which has been confirmed with endoscopy, and 
experiencing active gastrointestinal bleeding.
In patients were performed physical examination, 
laboratory examination, esophagoduodenoscopy, and 
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gastric biopsy in 4 areas (2 areas in antrum and 2 areas 
in corpus). Patients were further randomized into 
2 groups, fucoidan and placebo groups. Randomization 
was performed according to block permutation using 
table. Every patient received 1 tablet daily for 28 days. 
The reading of mucosal thickness was performed 
using ocular micrometer in light microscope with 
enlargement of 10 x 10 to determine the good specimen 
plate with 1 scale unit in ocular micrometer was 
equal to 10 micron.6 Reading of mucus thickness was 
performed in 4 random areas which has fulfilled criteria 
mention above and average of the results were taken. 
This reading was meant to overcome the intraobserver 
variability. Patient was then given a daily note on 
the progression of disease, symptoms, and checklist 
of medicines taken, and rescue drug, antacid, if there 
were symptoms during the course of the study. Later, 
re-monitoring was conducted to the patient by repeating 
the examinations, including physical examination, 
laboratory examination, esophagoduodenoscopy, and 
biopsy in 4 areas of the gaster (2 areas in the antrum 
and 2 areas in the corpus). 
Difference on the mucus thickness before and after 
intervention in each group was analyzed using paired 
T-test. Difference on the mucus thickness before and 
after therapy between the fucoidan and placebo group 
was analyzed using unpaired T-test. All analysis will be 
using 5% significancy, with 95% confidence interval. 
Data distribution was analyzed using Kolmogorov-
Smirnov test. In addition, analysis at the end of 
the study was conducted using per protocol principle 
analysis.
RESULTS
Of 41 patients who fulfilled the criteria and gave 
consent to participate in the study, 7 patients did 
not complete the study. There was no adverse effect 
found in patients who received fucoidan and placebo 
clinically or in laboratorium. Patients’ characteristics 
were described in Table 1. 
From histopathologic examination, 1 (2.4%) patient 
suffered from H. pylori infection in fucoidan group and 
after 28 days, the infection was negative. Laboratory 
results of hemoglobin, leukocytes, thrombocytes, 
ureum, creatinine, AST and ALT were similar in both, 
fucoidan and placebo group. Besides, in the analysis of 
mucus thickness variability based on comparing results 
of mucus thickness reading performed by researcher 
and an anatomy-pathologist, correlation of 0.954 was 
obtained.
Table 1. Patients' characteristics
Characteristic Fucoidann = 20
Placebo
n = 21
Age ± SD (years)
Sex (%)
Male
Female
Ethnics (%)
Javanese
Batak
Minangkabau
Sundanese
Betawi
Etc
Education level (%)
Master’s degree
Bachelor’s degree
Senior high school
Junior high school
Elementary school
No schooling
Etc
Occupation (%)
Government employee
Private employee
Entrepreneur
Student
Unemployment
Etc
Smoking (%)
Yes
No
Diabetes mellitus (%)
Yes
No
Hypertension (%)
Yes
No
Body mass index (%)
< 18.5
≥ 18.5
H. pylori infection
Yes
No
45.25 ± 11.86
10 (50)
10 (50)
10 (50)
4 (20)
3 (15)
2 (10)
0 (0)
1 (5)
1 (5)
3 (15)
7 (35)
4 (20)
0 (0)
2 (10)
3 (15)
3 (15)
2 (10)
2 (10)
1 (5)
7 (35)
5 (25)
7 (35)
13 (65)
3 (15)
17 (85)
4 (20)
16 (80)
2 (10)
18 (90)
1 (5)
19 (95)
40.81 ± 9.55
10 (47.6)
11 (52.4)
8 (38.1)
2 (9.5)
2 (9.5)
5 (23.8)
2 (9.5)
2 (9.5)
1 (4.8)
2 (9.5)
5 (23.8)
3 (14.3)
3 (14.3)
1 (4.8)
1 (4.8)
5 (23.8)
3 (14.3)
5 (23.8)
1 (4.8)
3 (14.3)
4 (19)
8 (38.1)
13 (61.9)
1 (4.8)
20 (95.2)
3 (14.3)
18 (85.7)
4 (19)
17 (81)
0 (0)
21 (100)
Laboratory examination
Hemoglobin ± SD (g/dL)
Leukocyte ± SD (/uL)
Thrombocyte ± SD (/uL)
Ureum ± SD (mg/dL)
Creatinine ± SD (mg/dL)
AST ± SD (mg/dL)
ALT ± SD (mg/dL)
13.3 ± 1.9
8,410 ± 2,170.3
335,150 ± 107,631
21.6 ± 7.4
0.8 ± 0.2
25.3 ± 10.1
25.6 ± 16.9
13.5 ± 0.9
7,623.8 ± 1,861.7
319,571 ± 72,512
22.0 ± 8.9
0.8 ± 0.3
22.5 ± 6.7
19.1 ± 11.1
SD: standard deviation; H. pylori: Helicobacter pylori, AST: aspartate 
transaminase; ALT: alanine aminotransferase
There was no significant different on the antrum 
mucus thickness before initiation of therapy in 
fucoidan and placebo group (p = 0.17). Differently, 
there was significant difference of corpus 
mucus thickness before initiation of therapy in 
fucoidan and placebo group (p = 0.04) (Table 2). 
Table 2. Mucus thickness before initiation of therapy
µm (SD) Fucoidanµm (SD)
Placebo
µm (SD)
Antrum 42.59 (8.67) 40.69 (8.91) 44.40 (8.24) p = 0.17*
Corpus 44.28 (9.64) 41.16 (9.61) 47.26 (8.89) p = 0.04*
*Unpaired T-test
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 Antrum mucus thickness before and after 
therapy in each group showed significant difference. 
The difference of antrum mucus thickness before and 
after therapy between fucoidan and placebo group also 
showed significant difference (Table 3). 
The difference in corpus mucus thickness before 
and after therapy showed significant difference 
between fucoidan and placebo group (Table 4). Based 
on the difference of mucus thickness in antrum and 
corpus before and after therapy, significant difference 
was exhibited (Figure 1).
Table 3. Effect of fucoidan to antrum mucus thickness
Before
µm (SD)
After
µm (SD)
∆
µm
Fucoidan 
(n=16)
39.10 (9.03) 51.52 (8.93) 12.42 p < 0.001*
Placebo 
(n=18)
44.51 (8.78) 49.51 8.10) 5.00 p = 0.002*
p = 0.001**
*Paired T-test; **Unpaired T-test; ∆: the difference of antrum mucus thickness 
before and after therapy
DISCUSSION
This study included chronic gastritis patients with 
similar characteristics between fucoidan and placebo 
group, in terms of sex, ethnics, occupation, and 
educational status. Demography characteristics in this 
study was similar to the study performed by Antono 
et al, on mucus thickness in patients with NSAIDs 
gastropathy and the study conducted by Jhuffrie et al 
on the effect of fucoidan towards gastric ulcer.6,7
In the mucus thickness variability based on the 
comparison of reading results of mucus thickness by 
researcher and an anatomy-pathologist, correlation 
Table 4. Effect of fucoidan to corpus mucus thickness
Before
µm (SD)
After
µm (SD)
∆
µm
Fucoidan 
(n = 16)
38.75  (8.93) 49.96 (7.56) 11.21 p < 0.001*
Placebo 
(n = 18)
47.29  (9.54) 50.76 (7.40) 3.47 p = 0.08*
p = 0.007**
*Paired T test; **Unpaired T-test; ∆: the difference of corpus mucus thickness 
before and after therapy
of 0.954 (very good) was acquired. Therefore, the 
interobserver variability was very small which showed 
that the reliability of the measurement was high. 
In this study, interim analysis was performed due 
to limited time and cost, and also due to suspicion 
of improvement in endoscopic appearance in some 
patients and no significant improvement in the other 
patients by using smaller significant value (p = 0.02).
Mucus thickness in the antrum was thinner compared 
to the corpus in patients with chronic gastritis. This is in 
concordance with the study of Antono et al, on mucus 
thickness in patients with NSAIDs gastropathy and 
also in line with histology theory of gastric mucosa 
in the corpus, in which epithelial cells were thicker 
and mucus cells were more abundant compared to 
antrum.7,8 Methods used in this study was similar 
with the methods used in the study conducted by 
Antono.7 However, in the study conducted by Allen 
et al, to mice, the mucus thickness of the antrum 
was thicker compared to the corpus.9 Data on mucus 
thickness of the antrum has been reported in the study 
conducted by Allen and Bickel et al. However, there 
was no previous data on mucus thickness in patients 
with chronic gastritis.10,11 Data from the study held 
by Jordan et al found that mucus thickness in normal 
individual was 144 µm, however using a different 
method from the method used in this study, in which 
modified staining of schif periodic/alcian blue was 
used, reported that this method was better compared 
to the conventional method used in this study. This 
is because the continuity and integrity of the mucus 
would be better seen.12 Compared to normal patients, 
mucus thickness in patients with chronic gastritis in 
this study was thinner. This is in accordance with 
the theory that in patients with chronic gastritis, there 
is inflammation of gastric mucosa which may disrupt 
the function of epithelial cells of the gastric mucosa 
in producing mucus.8
There are many medicines available to treat peptic 
ulcer, such as H2A, PPI, and sucralfate. From these 
medicines, studies are mostly directed to agressive 
factors and very few studies are directed to defensive 
factors. Before ulcer is developed, repeated stress to 
the epithelial of gastric mucosa occur.3 Several 
medicines are directed to overcome the agressive 
factors in the development of peptic ulcer and very 
few medicines are used to modify defensive factors. 
Mucus is the first defense mechanism in the stomach, 
which potentially prevents the development of peptic 
ulcer. Misoprostol, a prostaglandin analog, is also 
a potent medicine to inhibit gastric acid and stimulate 
Figure 1. Fucoidan effect to mucus thickness of gastric mucosa
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the development of gastric mucus. However, this 
medicine has many side effects, such as pain, 
abdominal cramping, and diarrhea.13 Conversely, 
fucoidan is believed to increase the mucus of gastric 
mucosa with no side effects.
The existence of significant difference on mucus 
thickness between fucoidan group and placebo 
in the antrum and corpus showed the presence of 
significant effect of fucoidan towards mucus thickness 
of gastric mucosa. This effect is acquired through 
the cytoprotective effect and increase growth factor 
production on epithelial cells of the gastric mucosa.14 
With the presence of cytoprotective effect, the 
epithelial of mucosal surface may function optimally 
in producing mucus. Similarly, the presence of growth 
factors will enhance epithelial regeneration, so that 
mucus production by new epithelial cells will be 
better.13 Sucralfate also has cytoprotective effect, but 
has no effect in increasing growth factor production in 
the epithelial cells of gastric mucosal surface and effect 
towards the thickness of mucus of gastric mucosa.
Study on fucoidan and clinical symptoms of 
dyspepsia has been performed previously by Jhuffrie 
et al, which concluded that fucoidan was able to 
improve dyspepsia symptoms in patients with gastric 
ulcer.6 Mechanism of symptoms improvement in that 
study was unclear. One of the hypotheses is that it 
increased the mucus thickness, and thus, the mucus 
thickness which was thought to be thinner than normal 
people would increase and would approximately 
achieve the normal mucus thickness and protected 
gastric mucosa.
There is no data on the value of mucus thickness 
which will exhibit dyspepsia symptoms. Through 
data collection on mucus thickness in chronic gastritis 
patients, it was predicted that with mucus thickness 
of < 50 µm, dyspepsia symptoms will be exhibited. 
Previous studies in normal individuals found that 
the thickness of gastric mucus was > 100 µm.10,11,12 
Nevertheless, a particular study to find the relationship 
between mucus thickness and dyspepsia symptoms is 
needed, in order to show the thickness of mucus which 
exhibit dyspepsia symptoms.
Although there was an increase of mucus thickness 
after administration of 100 mg fucoidan for 28 days, 
the mucus thickness has not reach the mucus thickness 
in normal individuals.12 Possibly, the administration 
of fucoidan in longer term will improve the mucus 
thickness similar to normal individuals, not only in 
chronic gastritis patients but also in patients with 
mucus thickness disturbance, such as in patients with 
NSAIDs induced gastropathy, H. pylori infection, or 
peptic ulcer. Yet, further studies are needed to prove it. 
Increase of mucus thickness induced by fucoidan 
may play role in preventing peptic ulcer. Nevertheless, 
particular study is needed for further evaluation. 
Besides preventive factors, fucoidan may also improve 
subjective dyspepsia symptoms, such as in the study 
performed by Jhuffrie et al.6 Currently, a study is 
conducted to determine the effect of fucoidan towards 
dyspepsia symptoms and improvement in endoscopy 
appearance in chronic gastritis patients.
Different with the study conducted by Jhuffrie 
et al, which used omeprazole, this study was 
performed to patients who were given fucoidan 
without administration of any other medicine, so that 
the direct effect of fucoidan could be seen without 
the influence of other medicines.6 However, in this 
study, the exclusion factors were many and was held 
in single centre with limited sample. Thus, it can be 
assumed that generalization of this study can only 
be done in patients with chronic gastritis, without 
liver function disturbance, heart failure, and others 
according to the selection criteria. In implementation 
to chronic gastritis patients in Indonesia, generally 
there should be multicentre study with the same study 
design and methods, to be assumed as representation 
of chronic gastritis patients in Indonesia. 
 CONCLUSION
Thickness of mucus in the antrum and corpus in 
patients with chronic gastritis was thinner compared to 
normal patients. Thus, administration of fucoidan may 
increase the thickness of mucus in antrum and corpus in 
patients with chronic gastritis in Cipto Mangunkusumo 
Hospital.
SUGGESTION
As a complementary to this study, further study 
is needed, including multicentre study to acquire 
the mucus thickness data, the effect of fucoidan 
towards mucus thickness in patients with chronic 
gastritis, standard mucus thickness which will exhibit 
dyspepsia symptoms. Besides, this further study is 
expected to represent the population of patients with 
chronic gastritis in Indonesia.
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